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Editorial Comment 
Myocardial Perfusion Imaging by 
Contrast Echocardiography: 
Where Are We Going?* 
RICHARD S. MELTZER, MD, FACC 
New York, New York 
The preceding article by Santoso et al. (1) and an experi-
mental study by Gillam et al. (2) in this issue of JACC 
represent a new phase of research into myocardial perfusion 
imaging by contrast echocardiography. The technique of 
myocardial perfusion imaging using contrast echocardiog-
raphy was first reported in the ariimal model in 1980 and 
1982 (3-5) and has undergone a period of rapid initial de-
velopment, as reflected in the recent contrast echocardi-
ography seminar in this Journal (6-13). Initial feasibility 
testing in animals has been successfully accomplished. The 
two aforementioned articles are part of this new phase of 
research that is necessary before this technique can become 
a clinical tool. 
Toxicity of echocardiographic myocardial perfusion 
imaging. Toxicity must be an important concern in the 
introduction of any new technique. The intracoronary in-
jection of microbubbles of air would seem, at first, to be a 
dubious venture because coronary air emboli are potentially 
fatal and clinicians have been trained that small amounts of 
air during left heart catheterization are to be excluded at all 
costs! Why then is this seemingly mad line of research being 
pursued? There are several observations suggesting that 
myocardial perfusion imaging by contrast echocardiography 
might have acceptable toxicity: I) Intravenous contrast has 
been in use for more than a decade and has acceptable 
toxicity (14); 2) injections into the left heart chambers and 
great vessels during routine cardiac catheterization and ar-
teriography yield dense ultrasonic contrast, yet have ac-
ceptable toxicity; 3) initial animal feasibility studies (3-13) 
have noted no significant toxicity, although toxicology has 
not been the principal objective of the work; and 4) initial 
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human studies intraoperatively (15) and now during cardiac 
catheterization (I) have not identified major toxicity. 
However, caution must be exercised. The proper way of 
assessing the toxicity of microbubbles in the microcircu-
lation is unknown. Pathologic (I) and traditional clinical, 
electrocardiographic, echocardiographic, hemodynamic and 
enzymatic variables of myocardial injury (2) must be care-
fully examined before myocardial perfusion imaging by con-
trast echocardiography becomes a routine clinical tool. Safety 
measures must be well defined, because it is clear that this 
technique has lethal potential. Furthermore, two recent an-
imal studies (16, 17)-one by Gillam et al. (2) in this issue-
have suggested, for the first time, that toxicity can be de-
tected during myocardial perfusion studies by contrast echo-
cardiography. Therefore, more animal toxicity studies must 
be done. At the same time, because human studies are in 
progress or are being planned in several research laboratories 
(initial studies during angioplasty are likely), toxicity must 
be an important concern. A registry of myocardial perfusion 
imaging by contrast echocardiography, an important tech-
nique for prospectively evaluating toxicity in human studies, 
is now being established. Interested investigators can con-
tact me or Dr. Steven Feinstein of the University of Chicago 
Medical Center for further details. 
Future directions. Several other aspects of contrast 
echocardiographic myocardial perfusion studies must be 
considered. For instance, the relation between microbubbles 
and ultrasonic images and how these are affected by the 
chest wall and suboptimal quality studies will have to be 
studied further if quantitation of myocardial perfusion can 
be achieved. Another problem to be confronted is the de-
velopment of new contrast agents. If transient "plugging" 
of the microvasculature is the cause of the recently suggested 
(16,17) toxicity of microbubbles, the development of con-
trast agents with "minimicrobubbles" small enough to pass 
through capillaries would be a way of avoiding this toxicity 
(6, 13). This approach might also have the advantage of 
allowing intravenous injections of a contrast agent that could 
survive transit through the pillmonary capillaries (18) and 
allow myocardial perfusion imaging. This ultimate goal-
"noninvasive" myocardial perfusion imaging by contrast 
echocardiography-was correctly identified by Corday et 
al. (19) in the introduction to the contrast echocardiography 
seminar as potentially having a major impact on the diag-
nosis and treatment of coronary disease. A good start has 
been made in this direction. 
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